Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Cardiovascular

Set Alert for Cardiovascular

Esperion Hopes CVOT Will Help Drive Nexletol/Nexlizet’s Market Uptake

The drugs have been slow to catch on since approval more than two years ago, but results showing reduction in cardiovascular events could help it gain traction.

Clinical Trials Cardiovascular

CinCor Plans Baxdrostat Phase III Despite Phase II Miss In Uncontrolled Hypertension

With subgroup analysis that it claims shows efficacy in non-Hispanics and success in a previous Phase II in treatment-resistant hypertension, CinCor plans to outline Phase III plans to FDA in early 2023.

Clinical Trials Business Strategies

CMO Eliav Barr On Merck & Co.'s Post-Keytruda Game Plan

Merck & Co. chief medical officer Eliav Barr talks with Scrip about the generational leadership change under way at the company, Merck's next oncology plays and its bold plan to rebuild a cardiovascular franchise.

Business Strategies Research & Development

Acticor Makes Case For First-In-Class Heart Drug Glencozimab

As it initiates the mid-stage clinical program for glencozimab, Acticor says that the potential of the drug in ischemic stroke alone could make it a blockbuster.

Cardiovascular Business Strategies

Mineralys Looks To Path Ahead For MLS-101 In Hypertension

The company plans to meet with the FDA before the end of the year to discuss the way forward, including a pivotal study it hopes to launch in 2023 in uncontrolled and resistant hypertension.

Business Strategies Clinical Trials

AstraZeneca To Remain In Vaccines For The Long Haul

The highs and lows experienced with its COVID-19 vaccine Vaxzevria have not deterred the UK giant from keeping a presence in the field and CEO Pascal Soriot told Scrip that the path could mirror the decade-long journey AstraZeneca had in oncology before it achieved sustained success.

Vaccines Sales & Earnings

Idorsia/J&J’s Aprocitentan Hits Phase III Mark, Could Become First ET-1 Antagonist For Hypertension

The first-in-class ET-1 receptor antagonist has met the primary endpoint in a pivotal resistant hypertension trial, sparking filing plans that could see the drug establish a stronghold in the multi-billion dollar market.

Clinical Trials Cardiovascular

Amgen’s Olpasiran Maintains Competitive Profile In Lp(a) Class

The lipoprotein(a)-lowering antisense drug olpasiran reduced the cardiovascular disease risk factor Lp(a) by up to 101.1% relative to placebo. A Phase III trial will begin in December. 

Clinical Trials Cardiovascular

Bayer Goes All In With Asundexian And Pulls Two Other Factor XIa Projects

Despite promising mid-stage data for the Ionis-partnered fesomersen and osocimab, licensed from Aronora, the German major has plumped for asundexian as the priority compound for its Factor XIa efforts.

Sales & Earnings Clinical Trials

Milestone Hits Mark With RAPID Path To Potential Blockbuster Sales

The company plans to file for approval of etripamil in paroxysmal supraventricular tachycardia (PSVT) in mid-2023, with the drug having the possibility to reach sales of $1bn or more.

Cardiovascular Drug Delivery Technology

Amarin Fights Flames Of Investor Unrest

Derided by largest shareholder Sarissa as ‘dawdling’ and ‘lackadaisical,’ the board at Amarin has come out fighting, saying that a strategy of growing its heart drug in Europe will pay dividends.

Business Strategies Cardiovascular

Merck’s Sotatercept Hits Phase III Marks In Mid-Stage PAH Patients

The pharma’s pulmonary arterial hypertension candidate, touted as a future blockbuster seller, showed benefit on six-minute walk distance and several secondary endpoints in Phase III STELLAR.

Clinical Trials Business Strategies
See All
UsernamePublicRestriction

Register